China Biologic Products Holdings, Inc. provided earnings guidance for the full year of 2017. For the period, the company’s total sales is expected to grow approximately 10.5% in RMB terms over 2016 results, compared to its previous revised guidance of 9%-10%, and announced that it is updating its full year non-GAAP adjusted net income growth rate to be in the low teens on a percentage basis compared to its previous guidance of non-GAAP adjusted net income growth of 18% to 20%.